title: Complete remission of a brain metastasis to third-line hormonal treatment with megestrol acetate.
abstract: The prognosis of patients with brain metastases from breast cancer is poor. Median survival after radiotherapy is 5-6 months. We report a patient in whom a complete response of a brain metastasis was induced by megestrol acetate at a daily dose of 160 mg orally.
authors.affiliation: Department of Medical Oncology, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: van der Gaast
authors.forename: J
authors.initials: J
authors.lastname: Alexieva-Figusch
authors.forename: C
authors.initials: C
authors.lastname: Vecht
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: G
authors.initials: G
authors.lastname: Stoter
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D001943:Breast Neoplasms / Q000473:pathology*; D002220:Carbamazepine / Q000627:therapeutic use; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008535:Megestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019290:Megestrol Acetate; D008875:Middle Aged; D010052:Ovariectomy; D012074:Remission Induction
chemical_list: D002220:Carbamazepine; D003907:Dexamethasone; D008535:Megestrol; D019290:Megestrol Acetate